Skip to main content
. 2021 Feb 11;9(1):91–101. doi: 10.1177/2050640620964619

FIGURE 3.

FIGURE 3

Clinical disease activity during ongoing infliximab (IFX) therapy from 1 year prior to pregnancy until 1 year after delivery in patients with (a) Crohn's disease (n = 15 pregnancies) or (b) ulcerative colitis (n = 5 pregnancies). Shown are mean with SEM. *p < 0.05 as compared to prepregnancy